CaseVu
Precipio’s HemeScreen™ Adopted By Methodist Health
New Molecular Screening Assay Technology Gains Traction NEW HAVEN, CT, (April 3, 2019) – Specialty diagnostics [...]
Apr
Precipio CEO Issues Shareholder Update Letter
NEW HAVEN, CT, (March 11th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following [...]
Mar
Precipio Provides Corporate Update Shareholder Call
Conference Call to be held Thursday February 21st, 2019 at 4:30pm Eastern Time NEW HAVEN, [...]
Feb
Precipio 2018 Revenues Increase 66% Over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability
Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) – [...]
Feb
Makati Medical Center In The Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology For Liquid Biopsies
One of Nation’s Premier Hospitals to Become Central Laboratory for Liquid Biopsies NEW HAVEN, CT, [...]
Jan
Precipio Announces First US Government Customer For ICE COLD-PCR™ Mutation Enrichment Technology
Department of Defense Approves Precipio as a Vendor for its Liquid Biopsy Testing NEW HAVEN, [...]
Jan
Precipio Files Patent For HemeScreen™, Its Novel Molecular Assay
Commercialization of assay underway with both in-house testing and hospital sales NEW HAVEN, CT, (January [...]
Jan
Precipio Reports Strong Mid-Quarter Growth
Key Metrics Indicate Continued Growth QoQ for Fourth Quarter 2018 NEW HAVEN, CT, (December 12th, [...]
Dec
Precipio Announces $1.2 Million Securities Purchase Agreement With Participation From Members Of Its Board Of Directors, And Other Investors
NEW HAVEN, CT, (December 4th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]
Dec
Precipio Announces Third Quarter 2018 Corporate Update Call For Shareholders
Conference Call to Be Held Monday, November 19, 2018 at 5:00 PM ET NEW HAVEN, [...]
Nov